Pasar al contenido principal

ESTRUCTURA Y MECANISMO MOLECULAR DE ACCION DE MODULADORES PPI DIRIGIDOS A NCS-1 PARA REGULAR LA SEÑALIZACION POR PROTEINAS G EN LA ENFERMEDAD DE PARKINSON PAPARKINSON

PID2022-137331OB-C31

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FDA Drug Repurposing Uncovers Modulators of Dopamine D2 Receptor Localization via Disruption of the NCS-1 Interaction

  • Muñoz-Reyes, Daniel
  • Aguado, Lorena
  • Arroyo-Urea, Sandra
  • Requena, Carlos
  • Pérez-Suárez, Sara
  • Sánchez-Yepes, Sonia
  • Argerich, Josep
  • Miró-Rodríguez, Celia
  • Ulzurrun, Eugenia
  • Rodríguez-Martín, Eulalia
  • García-Nafría, Javier
  • Campillo, Nuria E.
  • Mansilla, Alicia
  • Sánchez-Barrena, María José
Dopamine D2 receptor (D2 R) regulates key aspects of motor control, cognition, and reward. Its function depends not only on ligand binding and signaling efficacy but also on the dynamic control of receptor localization at the cell surface. Neuronal calcium sensor 1 (NCS-1) interacts with D2 R in a Ca2+ -dependent manner. Using in vitro and cellular assays, we found that NCS-1 promotes D2 R trafficking to the plasma membrane through active exocytosis while preserving canonical receptor pharmacology. A screen of FDA-approved drugs identified protein–protein interaction (PPI) modulators targeting the NCS-1/D2 R interface. Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D2 R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D2 R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D2 R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism., This work was supported by grants PID2019-111737RB-I00 and PID2022-137331OB-C31 (to M.J.S.B.); PID2020 113359GA-I00 and PID2023-148739NB-I00 (to J.G.N.);PID2022-137331OB-C32 (to A.M.); PID2022-137331OB-C33 (to N.E.C.); and the Spanish “Ramón y Cajal” program (to J.G.N. and A.M.), which were funded by the MICIU/AEI/ 10.13039/501100011033, FEDER and EU. S.P.S. was supported by a contract from the “Programa de Empleo Juvenil de la Comunidad de Madrid” PEJ-2020-AI/BMD 18666 and CMR by a Spanish National Research Council JAE Intro grant (JAEINT_23_00101)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

FDA Drug Repurposing Uncovers Modulators of Dopamine D<sub>2</sub> Receptor Localization via Disruption of the NCS-1 Interaction

  • Muñoz-Reyes, Daniel
  • Aguado, Lorena
  • Arroyo-Urea, Sandra
  • Requena, Carlos
  • Pérez-Suárez, Sara
  • Sánchez-Yepes, Sonia
  • Argerich, Josep
  • Miró-Rodríguez, Celia
  • Ulzurrun, Eugenia
  • Rodríguez-Martín, Eulalia
  • García-Nafría, Javier
  • Campillo, Nuria E.
  • Mansilla, Alicia
  • Sánchez-Barrena, María José
Dopamine D2 receptor (D2R) regulates key aspects of motor control, cognition, and reward. Its function depends not only on ligand binding and signaling efficacy but also on the dynamic control of receptor localization at the cell surface. Neuronal calcium sensor 1 (NCS-1) interacts with D2R in a Ca2+-dependent manner. Using in vitro and cellular assays, we found that NCS-1 promotes D2R trafficking to the plasma membrane through active exocytosis while preserving canonical receptor pharmacology. A screen of FDA-approved drugs identified protein–protein interaction (PPI) modulators targeting the NCS-1/D2R interface. Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D2R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D2R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D2R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism.